TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22136422

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (109 viable bacteria per day for 21 days)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 52
Study: 17607055

Group type: EXPERIMENTAL
Intervention: Pies Sanos intervention
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135

Group type: COMPARATOR
Intervention: Overall comparison between groups
Number of subjects: 135

Group type: COMPARATOR
Intervention: Baseline diabetes self-efficacy
Number of subjects: 135
Study: 17257460

Group type: EXPERIMENTAL
Intervention: Modafinil (100-400 mg, administered once daily or as a divided dose)
Number of subjects: 220
Study: 12603363

Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 178

Group type: COMPARATOR
Intervention: Psoriasis patients
Number of subjects: 178

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 178
Study: 10840295

Group type: EXPERIMENTAL
Intervention: Propranolol plus sclerotherapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 86
Study: 9589355

Group type: EXPERIMENTAL
Intervention: Indole-3-carbinol (I3C) 300 mg and 400 mg high-dose (HD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Indole-3-carbinol (I3C) 50 mg, 100 mg, 200 mg low-dose (LD)
Number of subjects: 60
Study: 8246267

Group type: EXPERIMENTAL
Intervention: IgG serum fractions from CF patients
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: IgG serum fractions from CF patients with strong inhibition
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: IgG subclass response to OMPs
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study: 3113800

Group type: EXPERIMENTAL
Intervention: Misoprostol 100 micrograms q.i.d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Misoprostol 50 micrograms q.i.d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Misoprostol 200 micrograms q.i.d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine 300 mg q.i.d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enprostil (another PGE2 analog)
Number of subjects: 0
Study: 30577546

Group type: EXPERIMENTAL
Intervention: Urban children
Number of subjects: 2020

Group type: COMPARATOR
Intervention: Rural children
Number of subjects: 2020

Group type: EXPERIMENTAL
Intervention: Overall children
Number of subjects: 2020

Group type: EXPERIMENTAL
Intervention: Overall dietary intake
Number of subjects: 2020
Study: 26876722

Group type: EXPERIMENTAL
Intervention: Telephone follow-up by study nurses with continuous contact, counseling on healthy living, and titration of medicines for blood pressure and blood lipids.
Number of subjects: 661

Group type: COMPARATOR
Intervention: Usual follow-up by a general practitioner.
Number of subjects: 661
Study: 24385282

Group type: EXPERIMENTAL
Intervention: Nephrotoxic group (n=77)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (n=149)
Number of subjects: 226
Study: 15735366

Group type: EXPERIMENTAL
Intervention: High-genistein isoflavone extract (HGI, 150 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12797715

Group type: EXPERIMENTAL
Intervention: King's Health Questionnaire (KHQ) administered at baseline and 12 weeks post-treatment
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: King's Health Questionnaire (KHQ)
Number of subjects: 1284
Study: 9748928

Group type: EXPERIMENTAL
Intervention: Non-occlusive dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Occlusive dressings
Number of subjects: 0
Study: 7620184

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 170
Study: 2096041

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment (Opium and Raphanus)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Opium + placebo
Number of subjects: 600

Group type: COMPARATOR
Intervention: Two placebos
Number of subjects: 600

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 600
Study: 660514

Group type: EXPERIMENTAL
Intervention: 10 mg of diazepam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29412008

Group type: EXPERIMENTAL
Intervention: Group A: unenhanced CT with 100 kVp, 200 mA and contrast-enhanced CT with spectral CT mode using low dose protocols.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Group B: conventional helical scanning with 120 kVp, auto mA for noise index of 12 HU for both unenhanced and contrast-enhanced CT.
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Group A: average radiation dose of 2.64 mSv.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Group B: average radiation dose of 6.18 mSv.
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Group A: total iodine intake of 13.5g.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Group B: total iodine intake of 21g.
Number of subjects: 64
Study: 27615044

Group type: EXPERIMENTAL
Intervention: Facial muscle exercise program including facial massage (20 minutes a day, 3 times a week for two weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Facial muscle exercise program including facial massage
Number of subjects: 70
Study: 24269096

Group type: EXPERIMENTAL
Intervention: High-flexion TKA
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard TKA
Number of subjects: 122
Study: 22334808

Group type: EXPERIMENTAL
Intervention: Auto-bilevel device
Number of subjects: 51

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups (Auto-bilevel and CPAP)
Number of subjects: 51
Study: 20862934

Group type: EXPERIMENTAL
Intervention: Acupuncture on different acupoints in combination with rehabilitation (group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional acupuncture in combination with rehabilitation training (group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rehabilitation training only (group C)
Number of subjects: 90
Study: 18849625

Group type: EXPERIMENTAL
Intervention: 3-ml volume of anesthetic solution
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 5-ml volume of anesthetic solution
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 7-ml volume of anesthetic solution
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 108
Study: 15803078

Group type: EXPERIMENTAL
Intervention: Head rotated to the left during rear-end impact
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Head rotated to the right during rear-end impact
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Increasing levels of acceleration (4.4, 7.9, 10.9, and 13.1 m/s)
Number of subjects: 20
Study: 11792336

Group type: EXPERIMENTAL
Intervention: Stress management training (1.5-hour weekly class)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3 times per week for 4 months)
Number of subjects: 94
Study: 10069869

Group type: EXPERIMENTAL
Intervention: Asthma duration (years)
Number of subjects: 1041
Study: 7578657

Group type: EXPERIMENTAL
Intervention: Oral mCPP (0.5 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous mCPP (0.1 mg/kg over 20 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2267922

Group type: EXPERIMENTAL
Intervention: Hydrocortisone and oral prednisolone for 5 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 509022

Group type: EXPERIMENTAL
Intervention: 92 dBA noise
Number of subjects: 0

Group type: COMPARATOR
Intervention: 75 dBA quiet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 92 dBA noise with suppressed rehearsal
Number of subjects: 0

Group type: COMPARATOR
Intervention: 75 dBA quiet with suppressed rehearsal
Number of subjects: 0
Study: 31930308

Group type: EXPERIMENTAL
Intervention: Immediate statin group (re‐initiation on the first postoperative day)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Late statin group (re‐initiation on the fifth postoperative day)
Number of subjects: 301
Study: 30621831

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Non-CBT-I (control group)
Number of subjects: 67
Study: 28872734

Group type: EXPERIMENTAL
Intervention: Xenon (50-65 vol%) plus sevoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane alone
Number of subjects: 40
Study: 26197184

Group type: EXPERIMENTAL
Intervention: H7N9 vaccine without adjuvant (15 µg hemagglutinin)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: H7N9 vaccine with AS03 adjuvant (15 µg hemagglutinin)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: H7N9 vaccine with MF59 adjuvant (15 µg hemagglutinin)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: 2 AS03-adjuvanted formulations
Number of subjects: 980
Study: 23660315

Group type: EXPERIMENTAL
Intervention: MYCu IUD
Number of subjects: 2000

Group type: COMPARATOR
Intervention: TCu380A IUD
Number of subjects: 2000
Study: 21368590

Group type: EXPERIMENTAL
Intervention: Influenza vaccine in HIV-infected pregnant women
Number of subjects: 38

Group type: COMPARATOR
Intervention: Influenza vaccine in uninfected pregnant women
Number of subjects: 38
Study: 19792840

Group type: EXPERIMENTAL
Intervention: Clinical evidence-based decision portals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardization of study-reporting criteria
Number of subjects: 0
Study: 16876891

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 542

Group type: COMPARATOR
Intervention: MT
Number of subjects: 542
Study: 15204893

Group type: EXPERIMENTAL
Intervention: Life Review Therapy (3 one-hour sessions)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Neutral video with follow-up discussion (control group)
Number of subjects: 14
Study: 11535325

Group type: EXPERIMENTAL
Intervention: Zanamivir 20 mg daily for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9753701

Group type: EXPERIMENTAL
Intervention: lormetazepam
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 7757392

Group type: EXPERIMENTAL
Intervention: Integrated Skills Reinforcement (ISR) method
Number of subjects: 93

Group type: COMPARATOR
Intervention: Lecture method (comparison group)
Number of subjects: 93
Study: 3058133

Group type: EXPERIMENTAL
Intervention: Muroctasin (MDP-Lys(L18)) at a dose of 200 micrograms, administered subcutaneously starting on day 4 after chemotherapy for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control cycle (standard chemotherapy protocol)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Muroctasin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control cycle
Number of subjects: 20
Study: 29392846

Group type: EXPERIMENTAL
Intervention: High flow nasal cannulae (HFNC) therapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 92
Study: 28086934

Group type: EXPERIMENTAL
Intervention: Real electroacupuncture/moxibustion treatments
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham electroacupuncture/moxibustion treatments
Number of subjects: 30
Study: 26331843

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist exenatide
Number of subjects: 48
Study: 23549993

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Portland Cement (PC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH)
Number of subjects: 45
Study: 21352431

Group type: EXPERIMENTAL
Intervention: 24% sucrose solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 40
Study: 18311768

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no psychological intervention)
Number of subjects: 47
Study: 17207378

Group type: EXPERIMENTAL
Intervention: COMBI (sulphasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Number of subjects: 195

Group type: COMPARATOR
Intervention: SINGLE (initially sulphasalazine with or without prednisolone)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: COMBI
Number of subjects: 195

Group type: COMPARATOR
Intervention: SINGLE
Number of subjects: 195
Study: 14586044

Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 30
Study: 10922432

Group type: EXPERIMENTAL
Intervention: Calcium antagonist therapy (diltiazem and verapamil)
Number of subjects: 817
Study: 8868770

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1531673

Group type: EXPERIMENTAL
Intervention: Cl2MDP (2‐dichloromethylene bisphosphonate), 600 mg in 500 mL of normal saline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (500 mL of normal saline)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cl2MDP
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cl2MDP and Placebo
Number of subjects: 24
Study: 6436855

Group type: EXPERIMENTAL
Intervention: Behavioural psychotherapy from a nurse therapist
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine care from their general practitioner (GP)
Number of subjects: 50
Study: 30665438

Group type: EXPERIMENTAL
Intervention: Integral movement therapy, 20 supervised sessions over 10 weeks, twice per week, approximately 1 hour per session.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional local movement therapy, 20 supervised sessions over 10 weeks, twice per week, approximately 1 hour per session.
Number of subjects: 0
Study: 30400924

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) supplement for 6 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 26967321

Group type: EXPERIMENTAL
Intervention: Bupropion pretreatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: MDMA (125 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24947817

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Nifedipine and Tamsulosin
Number of subjects: 1200
Study: 22701382

Group type: COMPARATOR
Intervention: BUV40 (backup rate of 40 bpm)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: OVP (overdrive ventricular pacing at 20 bpm above mean nocturnal heart rate)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison between BUV40 and OVP in patients without heart failure
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison between BUV40 and OVP in patients with heart failure
Number of subjects: 28

Group type: COMPARATOR
Intervention: Central AHI in patients without HF
Number of subjects: 28

Group type: COMPARATOR
Intervention: Central AHI in patients with HF
Number of subjects: 28

Group type: COMPARATOR
Intervention: Obstructive AHI in patients without HF
Number of subjects: 28

Group type: COMPARATOR
Intervention: Obstructive AHI in patients with HF
Number of subjects: 28
Study: 19539384

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: allopurinol 300 mg daily
Number of subjects: 42
Study: 17586712

Group type: EXPERIMENTAL
Intervention: Cantilever resin‐bonded fixed partial dentures
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional removable partial dentures
Number of subjects: 60
Study: 15848559

Group type: EXPERIMENTAL
Intervention: Modified release tacrolimus (MR tacrolimus) once daily (qD)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Prograf twice a day
Number of subjects: 70
Study: 12487387

Group type: EXPERIMENTAL
Intervention: Nelfinavir-containing regimen
Number of subjects: 0
Study: 9729588

Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8129130

Group type: EXPERIMENTAL
Intervention: Laryngeal mask insertion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 20
Study: 2808215

Group type: EXPERIMENTAL
Intervention: Meropenem 0.25 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Meropenem 0.5 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Meropenem 1.0 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Meropenem with probenecid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Meropenem (general)
Number of subjects: 6
Study: 1173199

Group type: EXPERIMENTAL
Intervention: Obex-LA (105 mg sustained action)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Obex (35 mg non-sustained action)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Obex-LA
Number of subjects: 9

Group type: COMPARATOR
Intervention: Obex
Number of subjects: 9
Study: 7013721

Group type: EXPERIMENTAL
Intervention: Oral mexiletine (200 mg 4 times daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral disopyramide (100 mg 4 times daily)
Number of subjects: 40
Study: 31002110

Group type: EXPERIMENTAL
Intervention: 1.5% CFP without PB
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.5% CaLS to the 3% SO diets
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1.5% CFP diets with 2% Ben
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 3% SO with 0.21 to 0.56% CaLS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Diets containing less than 2.86% SO with 0.5% CaLS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1.5 to 2.50% CFP diets without CaLS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Increasing CaLS levels more than 0.38%
Number of subjects: 22
Study: 29504795

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Number of subjects: 148
Study: 27969025

Group type: EXPERIMENTAL
Intervention: BREATHE: Stress Management for Nurses program
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 24395850

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 111
Study: 22681782

Group type: EXPERIMENTAL
Intervention: 6-item PCS-D anxiety measure
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 3-factor model
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Subscales of the 3-factor model
Number of subjects: 450
Study: 19054012

Group type: EXPERIMENTAL
Intervention: 50 microg ghrelin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17876852

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide spray (1-2 sprays, maximum of 4 times per day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide spray
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 15107190

Group type: EXPERIMENTAL
Intervention: Mirtazapine in addition to standard treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard detoxification protocol
Number of subjects: 68
Study: 11579987

Group type: EXPERIMENTAL
Intervention: Suppression of obsessional thoughts
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Suppression of positive thoughts
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Suppression of neutral thoughts
Number of subjects: 219

Group type: COMPARATOR
Intervention: No suppression (control group)
Number of subjects: 219
Study: 9608880

Group type: EXPERIMENTAL
Intervention: Azelastine eye drops 0.025%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Azelastine eye drops 0.05%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Azelastine eye drops 0.1%
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7740443

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate 200 mg once daily
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate 200 mg twice daily
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate 300 mg twice daily
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard prophylactic agents
Number of subjects: 153
Study: 2736440

Group type: EXPERIMENTAL
Intervention: 7% glucose polymer solution, 0.5 L ingested 10 min before the game and at half-time (Experimental Team - ET)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo, equal volumes ingested at the same times (Control Team - CT)
Number of subjects: 10
Study: 46510

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion therapy (1 or more bags of granulocyte-rich plasma)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion therapy (1 bag of granulocyte-rich plasma)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion from normal donors
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion from C.G.L. donors
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion therapy
Number of subjects: 41
Study: 31876455

Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Number of subjects: 41

Group type: COMPARATOR
Intervention: Video feedback training
Number of subjects: 41
Study: 28179488

Group type: EXPERIMENTAL
Intervention: Enhanced interpersonal counseling (IPC) + mass media (MM) + community mobilization (CM) (intensive)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Standard IPC + less-intensive MM and CM (nonintensive)
Number of subjects: 1500
Study: 25771840

Group type: EXPERIMENTAL
Intervention: 1.7 g of n-3 PUFA
Number of subjects: 161

Group type: COMPARATOR
Intervention: 2 g of placebo (olive oil)
Number of subjects: 161
Study: 23534988

Group type: EXPERIMENTAL
Intervention: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) administered every 3 weeks (q3w)
Number of subjects: 0

Group type: COMPARATOR
Intervention: sb-paclitaxel administered every 3 weeks (q3w)
Number of subjects: 0

Group type: COMPARATOR
Intervention: sb-paclitaxel administered weekly
Number of subjects: 0
Study: 20666686

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (500 mg daily, 4 consecutive days per month for 3 consecutive months)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily for 3 consecutive months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100